Latest XyloCor Therapeutics News & Updates

See the latest news and media coverage for XyloCor. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
XyloCor Therapeutics (XyloCor)

Biotechnology company developing gene therapies for coronary artery disease

xylocor.com
Headquarters
King of Prussia, United States
Founded year
2013
Company type
Private company
Number of employees
19–50
Industry
Pharmaceuticals

Last updated

Latest news about XyloCor Therapeutics (XyloCor)

In short: XyloCor raised $67.5 million in Series B financing.

Company announcements

XyloCor

XyloCor reports positive Phase 2 results for XC001

The EXACT trial met safety and efficacy objectives, with no drug-related serious adverse events and reduced ischemic burden, chest pain episodes and improved exercise capacity in 28 patients at six months.

Unlock all announcements with a

Media coverage

Yahoo Finance

XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023

– Positive Phase 2 EXACT Trial results at 6-months underscore significant potential of investigational therapy in refractory angina – Six-month data have since been sustained...

Unlock all articles with a

Never miss news about XyloCor

Track XyloCor and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.